|Bid||1.6300 x 1800|
|Ask||1.6600 x 3200|
|Day's Range||1.5500 - 1.7000|
|52 Week Range||0.3010 - 2.3900|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Lipocine Inc. (NASDAQ:LPCN) is possibly approaching a major achievement in its business, so we would like to shine...
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that it is working towards taking action on the TLANDO New Drug Application ("NDA") on or about the week of November 30, 2020. However, the Company cannot assure that the FDA will act in that time frame.